Current Report Filing (8-k)
December 06 2019 - 4:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 4, 2019
IMMUNIC, INC.
(Exact name of registrant as specified
in its charter)
Delaware
|
001-36201
|
56-2358443
|
(State or other jurisdiction
of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
|
|
1200 Avenue of the Americas, Suite
200
New York, NY 10036
USA
|
|
|
(Address of principal executive offices)
|
|
Registrant’s telephone number, including
area code: 49 89 250079460
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Title of each class
|
Trading symbol(s)
|
Name of each exchange
on which registered
|
Common Stock, $0.0001 par value
|
IMUX
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§ 240.12b2 of this chapter).
Emerging
growth company ý
If an emerging growth company, indicate by check mark if
the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange
Act. Yes ý No ¨
Item 8.01. Other Events
Effective December 4, 2019, the Board of
Directors (the “Board”) of Immunic, Inc. changed the composition of its committees. The current membership of
Board committees is as follows:
|
·
|
Audit Committee: Barclay Phillips (Chair),
Jan Van den Bossche and Jörg Neermann.
|
|
·
|
Compensation Committee: Tamar Howson (Chair)
and Jörg Neermann.
|
|
·
|
Nominating and Governance Committee: Vincent
Ossipow (Chair) and Jan Van den Bossche.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
|
|
|
|
|
Dated: December 6, 2019
|
|
|
|
Immunic, Inc.
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Daniel Vitt
|
|
|
|
|
|
|
Daniel Vitt
|
|
|
|
|
|
|
Chief Executive Officer
|
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immunic (NASDAQ:IMUX)
Historical Stock Chart
From Sep 2023 to Sep 2024